



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Barbara K. Finck et al.

Docket No.: 2945-A

Serial No.: 09/602,351

Group Art Unit: 1614

Filing Date: June 23, 2000

Examiner: to be assigned

For: SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR
TREATMENT OF MEDICAL DISORDERS

Assistant Commissioner for Patents
Washington, D.C. 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose a publication known to them which may be material to the patentability of this invention. The enclosed publication is listed on the attached Form PTO-1449. Kindly acknowledge receipt of this Statement and make the cited reference of record in the subject application.

Submission of this publication does not constitute an admission that it is "prior art" under 35 U.S.C. §102 or §103, and Applicant specifically reserves the right to antedate any such material as by a showing under 37 C.F.R. §1.131 or other method. Applicant submits that the claims of the above-captioned application are directed to subject matter that is patentably distinct from the disclosure of the above-cited reference.

To Applicants' knowledge, no office action on the merits has been mailed in the subject application. Thus, no fee is due for the filing of this information disclosure statement.

Respectfully submitted,

Diana K. Sheiness

Diana K. Sheiness
Registration No. 35,356

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: March 26, 2001

Signed

DeDe Lindholm
DeDe Lindholm

RECEIVED
MAR 30 2001

TECH CENTER 1600/2900